Ustekinumab Is Approved for Crohn Disease

Created by:

21 Nov 2016 - General
A new biologic agent was approved for treatment of moderate to severe Crohn Disease. Ustekinumab is the antibody to interleukin-12 and interleukin-23, was initially developed for the treatment of psoriasis and psoriatic arthritis. Ustekinumab is approved for patient with moderate to severe crohn disease, who failed or not tolerating immunomodulators or steroids, or failed or intolerant to anti TNF. The approved dosing for Ustekinumab will be 130 mg as an intravenous infusion for induction and t...
 (Total 106 words)